Foley Hoag Represents Dicerna in Recent Collaborations

October 29, 2018

Foley Hoag LLP represented Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) in two collaboration agreements with Eli Lilly and Company (NYSE: LLY) and Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), both announced in the last week.  Using Dicerna’s leading position in RNA interference (RNAi)-based therapeutics, these collaborations target neurodegeneration, pain and cardiometabolic indications in the case of Lilly and complement-mediated disease in the case of Alexion.

Headquartered in Cambridge, Mass., Dicerna is a biopharmaceutical company focusing on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. The company is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented.

On October 29, 2018, Dicerna announced a global licensing and research collaboration with Eli Lilly and Company focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain.

On October 24, 2018, Dicerna entered into a collaboration with Alexion Pharmaceuticals, Inc. to discover and develop RNA interference therapies for complement-mediated diseases.

The Foley Hoag team of Hemmie Chang, Karen Tepichin and Mark Potash represented Dicerna in the collaboration agreements with Lilly and Alexion.

For more information, visit